Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > is Alison taking a pay cut..she wiped out 90% of mkt cap

<< Previous

Bullboard Posts

Next >>

Comment by DIYGuyon Nov 14, 2017 8:50am

91 Views

Post# 26957702

RE:RE:is Alison taking a pay cut..she wiped out 90% of mkt cap

Really? I feel terrible. Think I would feel worse locking in my losses. That’s what will happen in the coming weeks for those that hold shares in unregistered accounts.

”Smart” money in at $1.16 PP. Time will tell if if was smart or not. The insiders did participate in the PP. Almost at 5 weeks into cohort 1.

I don’t think there will be too much excitement until they get the MTD for HNSCC and can start combination therapy with radiation. Isolate the P53 occurrences in 50% of HNSCC and hope they can get the same 4/7 results from the preclinical trials. That is the blue sky scenario.

I still don’t quite understand why the MTD isn’t the same from the gynaecology trial. I guess they want to get to a higher more effective dose. At least they started at 1mg and not .25mg.

<< Previous

Bullboard Posts

Next >>

Xplore Resources to expand position near Surge Lithium Project